TAB-28z

N/A

Report date: 2025/03/20 14:58:09

Base Information

Drug NameTAB-28z
Drug Alias Nameanti-MUC1 CAR T-cell therapy (OncoTAb/Leucid Bio/King’s College London/University of North Carolina)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMucin-1 modulators
TargetsMucin-1
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncoTab Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina, GreensboroLeucid Bio LtdOncoTab Inc +[4] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A